Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 21;11:5573–5587. doi: 10.2147/CMAR.S200707

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Liu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Increase of miR-1-3p level inhibited the origination of the EMT process in RCC cells. RT-PCR assay or Western blot assay were used to detect the (A) mRNA or (B) protein expression levels of the epithelial marker E-cadherin and the mesenchymal marker and transcription factor Slug in A498 or CAKI-1 cells. Results shown that mRNA or protein expression of E-cadherin was improved in the miR-1-3p group compared with control groups, although the mRNA or protein expression levels of Slug was decreased in A498 or CAKI-1 cells treated with miR-1-3p compared with control groups. (The first panel of (B) is a representative illustration of the results; n=3, *P<0.01 vs Non-Transfected cells).

Abbreviations: EMT, Epithelial-mesenchymal transition, RCC, Renal cell cancer.